Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day as well, given the clear and sunny skies — and delicious breezes — enveloping the Pharmalot campus this morning. This calls for celebration with a cup of stimulation, and we are opening a new package of wild mountain blueberry for the occasion. Spring, after all, is nearly upon us. What is upon us right now, however, is our ever-growing to-do list. Sound familiar? So … here are some items of interest. Have a great day, everyone. …
Even as the war in Ukraine has prompted an exodus of international companies — from fast-food chains and oil producers to luxury retailers — from Russia, U.S. and global drug companies said they would continue manufacturing and selling their products there, Kaiser Health News tells us. Drug and device makers, which are exempted from U.S. and European sanctions, maintain that Russians need access to medicines and equipment and contend international humanitarian law requires they keep supply chains open. But Pfizer (PFE) chief executive officer Albert Bourla tells CBS News the company does not plan to invest further in Russia.
Legislation to limit insulin costs for people with diabetes is getting revived in the U.S. Senate, the Associated Press says. Democrats say they want to move quickly, but will need Republican support to get anything through an evenly divided chamber. The goal reemerged this week after Senate Majority Leader Chuck Schumer (D-N.Y.) wrote colleagues “negotiations are underway with Senate Republicans on legislation to lower the cost of insulin,” part of an urgent push to address economic pain points for American families. Democrats want to regain momentum on drug costs they frittered away when endless rounds of intra-party disagreements stalled President Biden’s domestic agenda
Create a display name to comment
This name will appear with your comment